– UK, Brentford – GlaxoSmithKline announces that Dr Jesse Goodman has been appointed to the Board of the Company as a Non-Executive Director and Scientific and Medical Expert with effect from 1 January 2016.
Commenting on the appointment, Philip Hampton, Chairman, said “I am delighted that Jesse is joining the Board.
Jesse is a leader in public health who brings a wealth of expertise spanning science, medicine, vaccines, regulation and public health, and has a proven record in addressing pressing public health needs from both the academic and federal sectors, which will be invaluable to GSK. My colleagues and I very much look forward to welcoming him to the Board.”
Dr Goodman, currently Professor of Medicine at Georgetown University, previously served in senior leadership positions at the US Food and Drug Administration (‘FDA’), including most recently as FDA’s chief scientist and previously as Director of the Center for Biologics Evaluation and Research (CBER).
Dr Goodman currently directs the Georgetown University Center on Medical Product Access, Safety and Stewardship (COMPASS) and is an active clinician who serves as Attending Physician in Infectious Diseases.
He received his degree in Biology from Harvard College, his doctorate from the Albert Einstein College of Medicine and his masters in public health from the University of Minnesota. Dr Goodman is Board Certified in Internal Medicine, Infectious Diseases and Oncology and has been elected to the American Society for Clinical Investigation and to the Institute (National Academy) of Medicine.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.